Pure and Organic CBD & and Hemp Products

Effective medicine provided by mother nature

  • Powerful relaxant

  • Strong painkiller

  • Stress reduction
  • Energy booster

Why CBD?

More and more renowned scientists worldwide publish their researches on the favorable impact of CBD on the human body. Not only does this natural compound deal with physical symptoms, but also it helps with emotional disorders. Distinctly positive results with no side effects make CBD products nothing but a phenomenal success.

This organic product helps cope with:

  • Tight muscles
  • Joint pain
  • Stress and anxiety
  • Depression
  • Sleep disorder

Range of Products

We have created a range of products so you can pick the most convenient ones depending on your needs and likes.

CBD Capsules Morning/Day/Night:

CBD Capsules

These capsules increase the energy level as you fight stress and sleep disorder. Only 1-2 capsules every day with your supplements will help you address fatigue and anxiety and improve your overall state of health.

Order Now

CBD Tincture

CBD Tincture

No more muscle tension, joints inflammation and backache with this easy-to-use dropper. Combined with coconut oil, CBD Tincture purifies the body and relieves pain. And the bottle is of such a convenient size that you can always take it with you.

Order Now

Pure CBD Freeze

Pure CBD Freeze

Even the most excruciating pain can be dealt with the help of this effective natural CBD-freeze. Once applied on the skin, this product will localize the pain without ever getting into the bloodstream.

Order Now

Pure CBD Lotion

Pure CBD Lotion

This lotion offers you multiple advantages. First, it moisturizes the skin to make elastic. And second, it takes care of the inflammation and pain. Coconut oil and Shia butter is extremely beneficial for the health and beauty of your skin.

Order Now

Cbd freeze pain relief roll one

reduce of Mechanism blood pressure? CBD to action

zhakin_s
04.06.2018

Content:

  • reduce of Mechanism blood pressure? CBD to action
  • mindbodygreen
  • Must Reads
  • Jun 15, The aim of this study was to investigate if CBD reduces BP in humans. . Effect of CBD on cardiovascular parameters mental stress. . other mechanism), thereby preventing an increase in blood pressure and cardiac output. The high ethanol preference of young mice is reduced by the cannabinoid . The combination of THC with the nonpsychotropic cannabis constituent CBD has a .. that these beneficial effects may be mediated by nonCB1 receptor mechanisms. . With repetitive dosing supine bradycardia and decreased blood pressure. 6 days ago The scientific debate has been going on for years whether marijuana has an effect on the cardiovascular system. Marijuana CBD and blood.

    reduce of Mechanism blood pressure? CBD to action

    Expert Opin Emerg Drugs. Expert Opin Investig Drugs. Adenosine A2a blockade prevents synergy between mu-opiate and cannabinoid CB1 receptors and eliminates heroin-seeking behavior in addicted rats. Unresponsiveness to cannabinoids and reduced addictive effects of opiates in CB1 receptor knockout mice. The roles of cannabinoid and dopamine receptor systems in neural emotional learning circuits: Cell Mol Life Sci. Cannabinoid CB1 receptor antagonists as promising new medications for drug dependence.

    J Pharmacol Exp Ther. Cognitive functioning of longterm heavy cannabis users seeking treatment. Chronic cognitive impairment in users of 'ecstasy' and cannabis. Cannabis use, cognitive performance and mood in a sample of workers. Long-term effects of frequent cannabis use on working memory and attention: Maternal smoking, drinking or cannabis use during pregnancy and neurobehavioral and cognitive functioning in human offspring.

    A literature review of the consequences of prenatal marihuana exposure. An emerging theme of a deficiency in aspects of executive function. Cannabis, the mind and society: Cannabis and cognitive dysfunction: The psychotomimetic effects of intravenous deItatetrahydrocannabinol in healthy individuals: Amotivational syndrome in organic solvent abusers.

    Characteristics of abnormal behavior induced by delta 9-tetrahydrocannabinol in rats. Psychiatric aspects of cannabis use in adolescents and young adults. Related, induced and associated psychiatric disorders to cannabis. Operant acquisition of marihuana in man. Cannabis, motivation, and life satisfaction in an internet sample. Subst Abuse Treat Prev Policy. Endocannabinoids in the regulation of appetite and body weight.

    Endocannabinoids in appetite control and the treatment of obesity. Genetic variations at the endocannabinoid type 1 receptor gene CNR1 are associated with obesity phenotypes in men. J Clin Endocrinol Metab. Lack of tolerance to the suppressing effect of rimonabant on chocolate intake in rats. The role of CB1 receptors in sweet versus fat reinforcement: SR , a CB1 cannabinoid receptor antagonist, selectively reduces sweet food intake in marmoset.

    Efficacy of rimonabant and other cannabinoid CB1 receptor antagonists in reducing food intake and body weight: Fighting obesity and associated risk factors by antagonising cannabinoid type 1 receptors. Effects of rimonabant on metabolic risk factors in overweight patients with dyslipidemia. N Engl J Med. Effect of rimonabant, a cannabinoid-1 receptor blocker, on weight and cardiometabolic risk factors in overweight or obese patients: Effects of the cannabinoid-1 receptor blocker rimonabant on weight reduction and cardiovascular risk factors in overweight patients: Clinical trials update and cumulative meta-analyses from the American College of Cardiology: Eur J Heart Fail.

    Rimonabant improves cardiometabolic risk profile in obese or overweight subjects: Rimonabant in obese patients with type 2 diabetes. Am J Health Syst Pharm. Long-term efficacy and safety of dronabinol for acquired immunodeficiency syndrome-associated anorexia.

    J Pain Symptom Manage. Dronabinol as a treatment for anorexia associated with weight loss in patients with AIDS. Dronabinol effects on weight in patients with HIV infection.

    The safety and pharmacokinetics of single-agent and combination therapy with megestrol acetate and dronabinol for the treatment of HIV wasting syndrome. Cannabinoids in the treatment of the cachexiaanorexia syndrome in palliative care patients. A phase II study of deltatetrahydrocannabinol for appetite stimulation in cancer-associated anorexia.

    Mechanism of action of cannabinoids: An efficient new cannabinoid antiemetic in pediatric oncology. Cannabinoids for control of chemotherapy induced nausea and vomiting: Therapeutic potential of cannabinoids in trigeminal neuralgia. Cannabinoids block release of serotonin from platelets induced by plasma from migraine patients. Int J Clin Pharmacol Res. Are oral cannabinoids safe and effective in refractory neuropathic pain?

    Lack of analgesic efficacy of oral deItatetrahydrocannabinol in postoperative pain. Pain relief with oral cannabinoids in familial Mediterranean fever. Efficacy of two cannabis based medicinal extracts for relief of central neuropathic pain from brachial plexus avulsion: Does the cannabinoid dronabinol reduce central pain in multiple sclerosis?

    Randomised double blind placebo controlled crossover trial. Effect of the synthetic cannabinoid dronabinol on central pain in patients with multiple sclerosis - secondary publication.

    The analgesic properties of deItatetrahydrocannabinol and codeine. Analgesic effect of deItatetrahydrocannabinol. Cannabis use for chronic non-cancer pain: Cannabis use in HIV for pain and other medical symptoms. Experience with the synthetic cannabinoid nabilone in chronic noncancer pain.

    Low dose treatment with the synthetic cannabinoid Nabilone significantly reduces spasticity-related pain: Analgesic effect of the synthetic cannabinoid CT-3 on chronic neuropathic pain: Cannabimimetic properties of ajulemic acid.

    A tale of two cannabinoids: Meta-analysis of cannabis based treatments for neuropathic and multiple sclerosis-related pain. Curr Med Res Opin. Initial experiences with medicinal extracts of cannabis for chronic pain: Randomized, controlled trial of cannabis-based medicine in central pain in multiple sclerosis. Combined cannabinoid therapy via an oromucosal spray.

    Cannabinoids for the treatment of pain: An update on recent clinical trials. Dexanabinol HU effect on experimental autoimmune encephalomyelitis: Excitotoxicity in a chronic model of multiple sclerosis: Neuroprotective effects of cannabinoids through CB1 and CB2 receptor activation. Cannabinoid CB1 and CB2 receptors and fatty acid amide hydrolase are specific markers of plaque cell subtypes in human multiple sclerosis.

    Changes in CB1 receptors in motor-related brain structures of chronic relapsing experimental allergic encephalomyelitis mice.

    Marihuana as a therapeutic agent for muscle spasm or spasticity. Control of spasticity in a multiple sclerosis model is mediated by CB1, not CB2, cannabinoid receptors. DeltaTHC in the treatment of spasticity associated with multiple sclerosis. Adv Alcohol Subst Abuse. Nabilone in the treatment of multiple sclerosis. Effect of cannabinoids on spasticity and ataxia in multiple sclerosis. Treatment of human spasticity with deltatetrahydrocannabinol.

    The effect of orally and rectally administered delta 9-tetrahydrocannabinol on spasticity: Int J Clin Pharmacol Ther. Tremor in multiple sclerosis. Safety, tolerability, and efficacy of orally administered cannabinoids in MS. Short-term effects of smoking marijuana on balance in patients with multiple sclerosis and normal volunteers. Tetrahydrocannabinol for tremor in multiple sclerosis. The effect of cannabis on tremor in patients with multiple sclerosis.

    Suppression of pendular nystagmus by smoking cannabis in a patient with multiple sclerosis. The effect of cannabis on urge incontinence in patients with multiple sclerosis: Curr Opin Investig Drugs. Efficacy, safety and tolerability of an orally administered cannabis extract in the treatment of spasticity in patients with multiple sclerosis: Do cannabis-based medicinal extracts have general or specific effects on symptoms in multiple sclerosis? A double-blind, randomized, placebo-controlled study on patients.

    Long-term use of a cannabis-based medicine in the treatment of spasticity and other symptoms in multiple sclerosis. Cannabinoids for treatment of spasticity and other symptoms related to multiple sclerosis CAMS study: Cannabinoids in multiple sclerosis CAMS study: J Neurol Neurosurg Psychiatry.

    From anecdotal evidence of cannabinoids in multiple sclerosis to emerging new therapeutical approaches. Cannabinoids in MS - are we any closer to knowing how best to use them? The endocannabinoid pathway in Huntington's disease: Cannabinoid system and neuroinflammation: Cannabinoids provide neuroprotection against 6-hydroxydopamine toxicity in vivo and in vitro: Neuroprotective cannabinoid receptor antagonist SRA prevents downregulation of excitotoxic NMDA receptors in the ischemic penumbra.

    Dexanabinol HU in the treatment of severe closed head injury: Efficacy and safety of dexanabinol in severe traumatic brain injury: Cannabinoid-based drugs as anti-inflammatory therapeutics. Anti-inflammatory property of the cannabinoid agonist WIN in a rodent model of chronic brain inflammation. Low dose oral cannabinoid therapy reduces progression of atherosclerosis in mice. Involvement of the cannabimimetic compound, N-palmitoyl-ethanoIamine, in inflammatory and neuropathic conditions: Review of the available pre-clinical data, and first human studies.

    Cannabidiol attenuates high glucose-induced endothelial cell inflammatory response and barrier disruption. Effect of the cannabinoid CB1 receptor antagonist rimonabant on nociceptive responses and adjuvant-induced arthritis in obese and lean rats.

    CB1 cannabinoid receptor signalling in Parkinson's disease. The cannabinoid receptor agonist WIN 55, reduces D2, but not D1, dopamine receptor-mediated alleviation of akinesia in the reserpine-treated rat model of Parkinson's disease. Effects of levodopa on endocannabinoid levels in rat basal ganglia: Effects of rimonabant, a selective cannabinoid CB1 receptor antagonist, in a rat model of Parkinson's disease.

    High endogenous cannabinoid levels in the cerebrospinal fluid of untreated Parkinson's disease patients. Endocannabinoid-mediated rescue of striatal LTD and motor deficits in Parkinson's disease models.

    Cannabinoids reduce levodopa-induced dyskinesia in Parkinson's disease: DeIta9-tetrahydrocannabinol improves motor control in a patient with musician's dystonia. Cannabis for dyskinesia in Parkinson disease: Randomised, double-blind, placebo-controlled trial to assess the potential of cannabinoid receptor stimulation in the treatment of dystonia.

    Neurokinin B, neurotensin, and cannabinoid receptor antagonists and Parkinson disease. Survey on cannabis use in Parkinson's disease: AIsasua del Valle A. Implication of cannabinoids in neurological diseases.

    An overview of Parkinson's disease and the cannabinoid system and possible benefits of cannabinoid-based treatments. Potential role of cannabinoids in Parkinson's disease. The pattern of neurodegeneration in Huntington's disease: Selective vulnerability in Huntington's disease: Loss of cannabinoid receptors in the substantia nigra in Huntington's disease. Arvanil, a hybrid endocannabinoid and vanilloid compound, behaves as an antihyperkinetic agent in a rat model of Huntington's disease.

    The cannabinoid receptor agonist WIN 55, attenuates the effects induced by quinolinic acid in the rat striatum. Controlled clinical trial of cannabidiol in Huntington's disease. Cannabinoids reduce symptoms of Tourette's syndrome. Delta 9-tetrahydrocannabinol THC is effective in the treatment of tics in Tourette syndrome: Tourette syndrome is not caused by mutations in the central cannabinoid receptor CNR1 gene.

    Marijuana in the management of amyotrophic lateral sclerosis. Am J Hosp Palliat Care. Increasing cannabinoid levels by pharmacological and genetic manipulation delay disease progression in SOD1 mice. AM , a cannabinoid CB2 receptor selective compound, delays disease progression in a mouse model of amyotrophic lateral sclerosis.

    The CB2 cannabinoid agonist AM prolongs survival in a transgenic mouse model of amyotrophic lateral sclerosis when initiated at symptom onset. Survey of cannabis use in patients with amyotrophic lateral sclerosis. A molecular link between the active component of marijuana and Alzheimer's disease pathology.

    Effects of dronabinol on anorexia and disturbed behavior in patients with Alzheimer's disease. Int J Geriatr Psychiatry. DeItatetrahydrocannabinol for nighttime agitation in severe dementia. Anticonvulsant activity of four oxygenated cannabidiol derivatives. Res Commun Chem Pathol Pharmacol. Antiepileptic potential of cannabidiol analogs. Structure-anticonvulsant activity relationships of cannabidiol analogs. Anticonvulsant effect of cannabidiol. S Afr Med J. Cannabidiol-antiepileptic drug comparisons and interactions in experimentally induced seizures in rats.

    Anticonvulsant interaction of cannabidiol and ethosuximide in rats. Potential therapeutical effects of cannabidiol in children with pharmacoresistant epilepsy. Cannabinoid CB1 receptor antagonists cause status epilepticus-Iike activity in the hippocampal neuronal culture model of acquired epilepsy. Arachidonyl-2'-chIoroethyIamide, a highly selective cannabinoid CB1 receptor agonist, enhances the anticonvulsant action of valproate in the mouse maximal electroshock-induced seizure model.

    Grand mal convulsions subsequent to marijuana use. Chronic administration of cannabidiol to healthy volunteers and epileptic patients. Cannabinoids in bipolar affective disorder: The use of cannabis as a mood stabilizer in bipolar disorder: Towards a cannabinoid hypothesis of schizophrenia: Anandamide levels in cerebrospinal fluid of first-episode schizophrenic patients: Impact of cannabis use.

    Clinical features of cannabis psychosis in schizophrenia patients. Cannabis and acute psychosis. Schizophrenia and cannabis consumption: A comparison of symptoms and family history in schizophrenia with and without prior cannabis use: Implications for the concept of cannabis psychosis. Lifetime positive symptoms in patients with schizophrenia and cannabis abuse are partially explained by co-morbid addiction.

    Placebo-controlled evaluation of four novel compounds for the treatment of schizophrenia and schizoaffective disorder. Antipsychotic effect of cannabidiol. Cannabidiol, a Cannabis sativa constituent, as an antipsychotic drug. Braz J Med Biol Res. Cannabidiol monotherapy for treatment-resistant schizophrenia.

    Enhancing cannabinoid neurotransmission augments the extinction of conditioned fear. Inhibition of fatty-acid amide hydrolase accelerates acquisition and extinction rates in a spatial memory task. Differential response to acute and repeated stress in cannabinoid CB1 receptor knockout newborn and adult mice.

    Drug use and validity of substance use self-reports in veterans seeking help for posttraumatic stress disorder. Depression in Parkinson's disease is related to a genetic polymorphism of the cannabinoid receptor gene CNR1.

    Antianxiety effect of cannabidiol in the elevated plus-maze. Anxiolytic effect of cannabidiol derivatives in the elevated plus-maze. A single dose study of nabilone, a synthetic cannabinoid. The efficacy and safety of nabilone a synthetic cannabinoid in the treatment of anxiety.

    The effects of marijuana on human sleep patterns. Effects of marihuana on sleeping states. Effects of marijuana extract and tetrahydrocannabinol on electroencephalographic sleep patterns. Effects of high dosage deItatetrahydrocannabinol on sleep patterns in man. Effect of Deltatetrahydrocannabinol and cannabidiol on nocturnal sleep and early-morning behavior in young adults. Effects of smoked marijuana in experimentally induced asthma.

    Am Rev Respir Dis. Respiratory status of seventy-four habitual marijuana smokers. Effect of oral administration of delta-tetrahydrocannabinol on airway mechanics in normal and asthmatic subjects. Acute effects of smoked marijuana and oral deltatetrahydrocannabinol on specific airway conductance in asthmatic subjects. Acute pulmonary physiologic effects of smoked marijuana and oral 9 -tetrahydrocannabinol in healthy young men.

    Acute and subacute bronchial effects of oral cannabinoids. Bronchodilator effect of deltaltetrahydrocannabinol. Br J Clin Pharmacol. Bronchodilator effect of deltaltetrahydrocannabinol administered by aerosol of asthmatic patients.

    Cardiovascular effects of intravenous deltatetrahydrocannabinol: The effects of deItatetrahydrocannabinol cannabis on cardiac performance with and without beta blockade. Short-term effects of smoked marihuana on left ventricular function in man. Cardiovascular effects of prolonged delta-9tetrahydrocannabinol ingestion. Cardiovascular and metabolic considerations in prolonged cannabinoid administration in man.

    The cannabinoid CB1 receptor antagonist rimonabant attenuates the hypotensive effect of smoked marijuana in male smokers. Cannabinoids in glaucoma II: Soft cannabinoid analogues as potential anti-glaucoma agents.

    Comparison of the enzymatic stability and intraocular pressure effects of 2-arachidonylglycerol and noladin ether, a novel putative endocannabinoid. Invest Ophthalmol Vis Sci.

    Effect of the enzyme inhibitor, phenylmethylsulfonyl fluoride, on the IOP profiles of topical anandamides. Ophthalmic arachidonylethanolamide decreases intraocular pressure in normotensive rabbits. Brain Res Mol Brain Res. Ocular hypotension, ocular toxicity, and neurotoxicity in response to marihuana extract and cannabidiol. Intraocular pressure, ocular toxicity and neurotoxicity after administration of cannabinol or cannabigerol.

    Intraocular pressure, ocular toxicity and neurotoxicity after administration of delta 9-tetrahydrocannabinol or cannabichromene. Marihuana smoking and intraocular pressure. Topical delta 9-tetrahydrocannabinol in hypertensive glaucomas. Because CBD modulates and regulates instead of simply binding, it does not produce addiction, habituation, tolerance, or reinforcement. Rather than requiring periodic increases to regain efficacy, once a person reaches "saturation," or their "subjective therapeutic dosing level," they can stay there and in some cases even decrease to a maintenance dose.

    Furthermore, because CBD is nonaddictive and does not bind to receptors, it is safe to cessate use immediately or "cold turkey" without the fear of withdrawal side effects. Finally, even though withdrawal effects are absent, if one discontinues the use of CBD, of course symptoms could return if CBD was previously helping.

    The hemp plant containing at or below 0. While the different levels of THC or other cannabinoids might make the effects seem different, the potency of CBD is the same.

    This is because the manufacturer must process far too much plant material to derive small amounts of CBD. To my knowledge, these proprietary genetics are still the highest in CBD concentration of any marijuana or hemp variety. You cannot take enough CBD to kill yourself or damage organs. This is not practically possible.

    First, let's discuss the LD rating of cannabis, which is ,, This is the ratio between a therapeutic and lethal dose. Comparatively, the LD for aspirin is 1: Two aspirin will take away a headache, 40 aspirin will kill 50 percent of the people who take that many. To cite a silly example, try to imagine someone smoking 40, joints in one sitting.

    Even with THC, you will fall asleep first. In short, cannabis compounds are some of the least toxic substances known to man. With this being said, you can still take "too much" and have an unpleasant experience, but permanent damage to the body or death are both out of the question.

    Want to try CBD for yourself? This lavender-infused CBD hot chocolate might be the most calming drink on the planet. Food has the power to create a happier and healthier world. Celebrity Nutritionist Kelly LeVeque will show you how. Functional Food icon functional food. Group 8 Created with Sketch. By Liz Moody Food Director.

    Group 7 Created with Sketch. Group 9 Created with Sketch. Group 10 Created with Sketch. Group 11 Created with Sketch. Email Created with Sketch. Group 4 Created with Sketch.

    How is CBD different from marijuana? What are the physiological health benefits of CBD? The list of benefits from inflammation to cancer seems almost too good to be true. One of the most common uses of CBD is for anxiety and insomnia. Has it been studied to actually make a difference for that? How does it work? How is CBD actually interacting with the brain and body?

    Are we totally sure that it's safe to consume? How can someone tell if they have high-quality CBD? Is there a particular dosage or amount of active compounds to look for? What effects can a person expect upon immediately taking CBD? What effects could they expect after a week, a month, or a year? If someone has a bad reaction to marijuana, would you recommend they stay away from CBD?

    Can CBD be addictive? If someone takes it daily, will they build up tolerance? Will they have any negative reactions when they stop? Is it possible to overdose on CBD? If so, what happens?

    Liz Moody Food Director. Liz Moody is the food director at mindbodygreen. Caroline Muggia 2 hours ago. Elizabeth Gerson 4 hours ago.

    mindbodygreen

    Feb 26, Recent research has linked CBD with several benefits for the heart and circulatory system, including the ability to lower high blood pressure. Aug 24, In numerous studies, CBD was able to reduce the number of seizures, and in some Side effects of CBD include nausea, fatigue and irritability. medications in your blood by the exact same mechanism that grapefruit juice does. .. balance · Controlling Your Blood Pressure · A Guide to Cognitive Fitness. Mar 30, Cannabinoids exert different effects on blood pressure depending on the route of cannabidiol (CBD) showed that CBD decreased blood pressure.4 In a small, with high potential for abuse like the addictiveness of heroin

    Must Reads



    Comments

    dancexx

    Feb 26, Recent research has linked CBD with several benefits for the heart and circulatory system, including the ability to lower high blood pressure.

    asidora2

    Aug 24, In numerous studies, CBD was able to reduce the number of seizures, and in some Side effects of CBD include nausea, fatigue and irritability. medications in your blood by the exact same mechanism that grapefruit juice does. .. balance · Controlling Your Blood Pressure · A Guide to Cognitive Fitness.

    uNcaInD27

    Mar 30, Cannabinoids exert different effects on blood pressure depending on the route of cannabidiol (CBD) showed that CBD decreased blood pressure.4 In a small, with high potential for abuse like the addictiveness of heroin

    naymov

    Cannabidiol is a pleiotropic drug in that it produces many effects through multiple It is involved in modulating blood pressure and bone density, among other But CBD interferes with this process by reducing anandamide's access to FABP key mechanism whereby CBD confers neuroprotective effects against seizures, .

    Add Comment